These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 20934535)

  • 21. A priori performance predictions in the pharmaceutical sciences.
    Hancock BC; Morris KR; Wildfong PL
    Int J Pharm; 2011 Oct; 418(2):149-50. PubMed ID: 21726614
    [No Abstract]   [Full Text] [Related]  

  • 22. Modelling and simulation in the pharmaceutical industry--some reflections.
    Burman CF; Wiklund SJ
    Pharm Stat; 2011; 10(6):508-16. PubMed ID: 22162317
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pediatric cardiovascular drug development and research: integration of modeling and simulation as one future direction.
    Läer S
    J Cardiovasc Pharmacol; 2011 Sep; 58(3):217-27. PubMed ID: 21654330
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Looking forward in pharmaceutical process chemistry.
    Davies IW; Welch CJ
    Science; 2009 Aug; 325(5941):701-4. PubMed ID: 19661417
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The Innovative Medicine Initiative (IMI)].
    Bril A; Canet E
    Med Sci (Paris); 2008 Oct; 24(10):885-90. PubMed ID: 18950588
    [TBL] [Abstract][Full Text] [Related]  

  • 26. What happened to the modeling and simulation revolution?
    Bonate PL
    Clin Pharmacol Ther; 2014 Oct; 96(4):416-7. PubMed ID: 25236664
    [No Abstract]   [Full Text] [Related]  

  • 27. Open-access public-private partnerships to enable drug discovery--new approaches.
    Müller S; Weigelt J
    IDrugs; 2010 Mar; 13(3):175-80. PubMed ID: 20191434
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Opportunities and challenges in the discovery of new central nervous system drugs.
    Krause JE; Chenard BL
    Ann N Y Acad Sci; 2008 Nov; 1144():243-50. PubMed ID: 19076381
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Integration of in silico and in vitro platforms for pharmacokinetic-pharmacodynamic modeling.
    Sung JH; Esch MB; Shuler ML
    Expert Opin Drug Metab Toxicol; 2010 Sep; 6(9):1063-81. PubMed ID: 20540627
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improving drug safety using computational biology.
    Cook D
    IDrugs; 2010 Feb; 13(2):85-9. PubMed ID: 20127559
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Drug Discovery Portal: a resource to enhance drug discovery from academia.
    Clark RL; Johnston BF; Mackay SP; Breslin CJ; Robertson MN; Harvey AL
    Drug Discov Today; 2010 Aug; 15(15-16):679-83. PubMed ID: 20547242
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of modeling and simulation: myth or fact?
    Allerheiligen SR
    Clin Pharmacol Ther; 2014 Oct; 96(4):413-5. PubMed ID: 25236663
    [No Abstract]   [Full Text] [Related]  

  • 33. A retrospective review of TATRC funding for medical modeling and simulation technologies.
    Pugh CM; Bevan MG; Duve RJ; White HL; Magee JH; Wiehagen GB
    Simul Healthc; 2011 Aug; 6(4):218-25. PubMed ID: 21546864
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Models for profiling the potential QT prolongation risk of drugs.
    Muzikant AL; Penland RC
    Curr Opin Drug Discov Devel; 2002 Jan; 5(1):127-35. PubMed ID: 11865666
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improving compound quality through in vitro and in silico physicochemical profiling.
    van de Waterbeemd H
    Chem Biodivers; 2009 Nov; 6(11):1760-6. PubMed ID: 19937820
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PK/PD modelling and simulations: utility in drug development.
    Rajman I
    Drug Discov Today; 2008 Apr; 13(7-8):341-6. PubMed ID: 18405847
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Visualization concepts to enhance quantitative decision making in drug development.
    Dykstra K; Pugh R; Krause A
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):130S-139S. PubMed ID: 20881226
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advances in knowledge management for pharmaceutical research and development.
    Torr-Brown S
    Curr Opin Drug Discov Devel; 2005 May; 8(3):316-22. PubMed ID: 15892246
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Challenges in the transition to model-based development.
    Grasela TH; Fiedler-Kelly J; Walawander CA; Owen JS; Cirincione BB; Reitz KE; Ludwig EA; Passarell JA; Dement CW
    AAPS J; 2005 Oct; 7(2):E488-95. PubMed ID: 16353926
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structure-based drug metabolism predictions for drug design.
    Sun H; Scott DO
    Chem Biol Drug Des; 2010 Jan; 75(1):3-17. PubMed ID: 19878193
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.